CD33 directed bispecific antibodies in acute myeloid leukemia

• Published in: Best practice & research. Clinical haematology 2020-12, Vol.33 (4), p.101224-101224, Article 101224
• Main Authors: Clark, Mary C., Stein, Anthony
• Format: Article
• Language: English
• Subjects: Acute myeloid leukemia; Bispecific antibodies; CD33; Cytokine release syndrome; Immunotherapy
• ISSN: 1521-6926; 1532-1924
• DOI: 10.1016/j.beha.2020.101224

Despite the approval of a number of new targeted therapies for acute myeloid leukemia (AML), median overall survival still remains poor, ranging from 12 to 18 months in most patients. Based on the success of blinatumomab, the CD19-targeted bispecific antibody for the treatment of acute lymphoblastic leukemia, the development of several CD33-targeted bispecific antibodies for AML are being investigated in clinical trials. In this review article of CD33-targeted bispecific antibodies, we describe the rationale for targeting CD3 x CD33, summarize the data from four ongoing phase 1 studies, review the major toxicity associated with CD33-targeted bispecific antibody therapy of cytokine release syndrome (CRS) and steps to mitigate CRS, and describe possible mechanisms of resistance to CD33-targeted bispecific antibody therapy. Future development to try to improve outcomes include combination therapies to reduce the tumor burden prior to starting treatment, combining with immune checkpoint inhibition therapy such as anti-PD-1/PDL1 antibodies, and the use of second generation bispecific antibodies that target two different antigens and recruit other effector cells such as nature killer cells and macrophages.